Expert prior elicitation and bayesian analysis of the mycotic ulcer treatment trial I

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 6, 2013, Pages 4167-4173

  Sun, Catherine Q ^a   Prajna, N Venkatesh ^b   Krishnan, Tiruvengada ^b   Mascarenhas, Jeena ^b   Rajaraman, Revathi ^b   Srinivasan, Muthiah ^b   Raghavan, Anita ^b   O'Brien, Kieran S ^a   Ray, Kathryn J ^a   McLeod, Stephen D ^a,c   Porco, Travis C ^a,c   Acharya, Nisha R ^a,c   Lietman, Thomas M ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ARAVIND EYE CARE SYSTEM   (India)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bayesian; Clinical trial; Corneal ulceration; Fungal keratitis; Statistics

Indexed keywords

NATAMYCIN; PLACEBO; VORICONAZOLE;

ARTICLE; BAYES THEOREM; CORNEA ULCER; DRUG EFFICACY; HEALTH SURVEY; HUMAN; KERATOMYCOSIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL ANALYSIS; TREATMENT OUTCOME; VISUAL ACUITY;

BAYESIAN; CLINICAL TRIAL; CORNEAL ULCERATION; FUNGAL KERATITIS; STATISTICS;

ANTIFUNGAL AGENTS; BAYES THEOREM; CORNEAL ULCER; EXPERT TESTIMONY; EYE INFECTIONS, FUNGAL; FUSARIOSIS; HUMANS; NATAMYCIN; PYRIMIDINES; QUESTIONNAIRES; TRIAZOLES;

EID: 84879187553     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-11716     Document Type: Article

References (32)

1. Whitcher JP, Srinivasan M, Upadhyay MP. Corneal blindness: a global perspective. BullWorld Health Organ. 2001;79:214-221.
2. Srinivasan M, Gonzales CA, George C, et al. Epidemiology and aetiological diagnosis of corneal ulceration in Madurai, south India. Br J Ophthalmol. 1997;81:965-971.
3. Srinivasan M. Fungal keratitis. Curr Opin Ophthalmol. 2004; 15:321-327.
4. Alfonso EC, Cantu-Dibildox J, Munir WM, et al. Insurgence of Fusarium keratitis associated with contact lens wear. Arch Ophthalmol. 2006;124:941-947.
5. Alfonso EC, Miller D, Cantu-Dibildox J, O'Brien TP, Schein OD. Fungal keratitis associated with non-therapeutic soft contact lenses. Am J Ophthalmol. 2006;142:154-155.
6. Margolis TP, Whitcher JP. Fusarium-a new culprit in the contact lens case. JAMA. 2006;296:985-987.
7. Prajna NV, Krishnan T, Mascarenhas J, et al. The Mycotic Ulcer Treatment Trial: a randomized trial comparing natamycin vs voriconazole. Arch Ophthalmol. 2012;Dec 10:1-8.
8. Chaloner K, Rhame FS. Quantifying and documenting prior beliefs in clinical trials. Stat Med. 2001;20:581-600.
9. Dolan JG, Bordley DR, Mushlin AI. An evaluation of clinicians' subjective prior probability estimates. Med Decis Making. 1986;6:216-223.
10. Brophy JM, Joseph L. Placing trials in context using Bayesian analysis. GUSTO revisited by Reverend Bayes. JAMA. 1995; 273:871-875.
11. Lee JJ, Chu CT. Bayesian clinical trials in action. Stat Med. 2012;31:2955-2972.
12. Hiance A, Chevret S, Levy V. A practical approach for eliciting expert prior beliefs about cancer survival in phase III randomized trial. J Clin Epidemiol. 2009;62:431-437.
13. Johnson NP, Fisher RA, Braunholtz DA, Gillett WR, Lilford RJ. Survey of Australasian clinicians' prior beliefs concerning lipiodol flushing as a treatment for infertility: a Bayesian study. Aust N Z J Obstet Gynaecol. 2006;46:298-304.
14. Johnson SR, Tomlinson GA, Hawker GA, Granton JT, Grosbein HA, Feldman BM. A valid and reliable belief elicitation method for Bayesian priors. J Clin Epidemiol. 2010;63:370-383.
15. Prajna NV, Mascarenhas J, Krishnan T, et al. Comparison of natamycin and voriconazole for the treatment of fungal keratitis. Arch Ophthalmol. 2010;128:672-678.
16. Gopinathan U, Garg P, Fernandes M, Sharma S, Athmanathan S, Rao GN. The epidemiological features and laboratory results of fungal keratitis: a 10-year review at a referral eye care center in South India. Cornea. 2002;21:555-559.
17. See CW, Srinivasan M, Saravanan S, et al. Prior elicitation and Bayesian analysis of the steroids for corneal ulcers trial. Ophthalmic Epidemiol. 2012;19:407-413.
18. Spiegelhalter DJ, Myles JP, Jones DR, Abrams KR. Bayesian methods in health technology assessment: a review. Health Technol Assess. 2000;4:1-130.
19. Lee PM. Bayesian Statistics: An Introduction. John Wiley and Sons; 2004.
20. Austin PC, Brunner LJ, Hux JE. Bayeswatch: an overview of Bayesian statistics. J Eval Clin Pract. 2002;8:277-286.
21. Gelman A, Carlin JB, Stern HS, Rubin DB. Bayesian Data Analysis. London: Chapman and Hall; 1995.
22. Loh AR, Hong K, Lee S, Mannis M, Acharya NR. Practice patterns in the management of fungal corneal ulcers. Cornea. 2009;28:856-859.
23. Lalitha P, Prajna NV, Oldenburg CE, et al. Organism, minimum inhibitory concentration, and outcome in a fungal corneal ulcer clinical trial. Cornea. 2012;31:662-667.
24. Lalitha P, Shapiro BL, Srinivasan M, et al. Antimicrobial susceptibility of Fusarium, Aspergillus, and other filamentous fungi isolated from keratitis. Arch Ophthalmol. 2007;125:789-793.
25. Marangon FB, Miller D, Giaconi JA, Alfonso EC. In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens. Am J Ophthalmol. 2004; 137:820-825.
26. O'Day DM. Selection of appropriate antifungal therapy. Cornea. 1987;6:238-245.
27. Thiel MA, Zinkernagel AS, Burhenne J, Kaufmann C, Haefeli WE. Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis. Antimicrob Agents Chemother. 2007;51:239-244.
28. Lau D, Fedinands M, Leung L, et al. Penetration of voriconazole, 1%, eyedrops into human aqueous humor: a prospective openlabel study. Arch Ophthalmol. 2008;126:343-346.
29. Kofla G, Ruhnke M. Voriconazole: review of a broad spectrum triazole antifungal agent. Expert Opin Pharmacother. 2005;6: 1215-1229.
30. Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs. 2004;64:1997-2020.
31. Rex JH, Pfaller MA. Has antifungal susceptibility testing come of age? Clin Infect Dis. 2002;35:982-989.
32. Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis. 1997;24:235-247.